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Abstract
Background: The incidence of rectal neuroendocrine tumors (NETs) is rapidly increasing because of the frequent
use of endoscopic screening for colorectal cancers. However, the clinical outcomes of endoscopic resection for
rectal NETs are still unclear. The aim of this study was to assess the rates of histologically complete resection
(H-CR) and recurrence after endoscopic mucosal resection (EMR) for rectal NETs.
Methods: A retrospective analysis was performed on patients who underwent EMR for rectal NETs between
January 2002 and March 2015 at Seoul National University Hospital. Primary outcomes were H-CR and recurrence
rates after endoscopic resection. H-CR was defined as the absence of tumor invasion in the lateral and deep margins of
resected specimens.
Results: Among 277 patients, 243 (88%) were treated with conventional EMR, 23 (8%) with EMR using a dual-channel
endoscope, and 11 (4%) with EMR after precutting. The median tumor size was 4.96 mm (range, 1–22) in diameter, and
264 (95%) lesions were confined to the mucosa and submucosal layer. The en-bloc resection rate was 99% and all
patients achieved endoscopically complete resection. The H-CR rates were 75, 74, and 73% for conventional
EMR, EMR using a dual-channel endoscope, and EMR after precutting, respectively. Multivariate analysis showed that H-
CR was associated with tumor size regardless of endoscopic treatment modalities (p = 0.023). Of the 277 patients, 183
(66%) underwent at least 1 endoscopic follow-up. Three (2%) of these 183 patients had tumor recurrence, which was
diagnosed at a median of 62.5 months (range 19–98) after endoscopic resection. There was 1 case of disease-related
death, which occurred 167 months after endoscopic treatment because of bone marrow failure that resulted from
tumor metastasis.
Conclusions: Although the en-bloc resection rate was 99% in rectal NETs, H-CR rates were 72–74% for various EMR
procedures. H-CR may be associated with tumor size regardless of endoscopic treatment modalities.
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Background
Rectal neuroendocrine tumors (NETs) are uncommon
tumors that account for approximately 10 to 17% of
NETs [1]. The rectum is the third most common site of
occurrence for NETs. Recently, the incidence of rectal
NETs has rapidly increased worldwide, partly owing to
rapid advances in screening endoscopy for colorectal
cancer [2].
Several parameters have been suggested as predictive
factors for malignant potential, including size, histological
growth patterns, muscularis propria invasion, and lym-
phovascular invasion (LVI) [3]. At the time of diagnosis,
approximately 80% of rectal NETs are smaller than
10 mm in diameter and do not show invasion or metasta-
sis [4]. For small rectal NETs, the risk of metastasis is very
low and local resection is thought to be curative [5, 6].
According to a previous study, metastasis occurs for less
than 3% of tumors smaller than 10 mm in diameter, 5–
15% of tumors 10–19 mm in diameter, and 80% of tumors
at least 20 mm in diameter [7]. Endoscopic resection is
widely accepted because of its minimal invasiveness, low
cost, better quality of life after treatment, and patient
tolerance. Rectal NETs that are smaller than 16 mm and
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do not show lymphatic or distant metastasis can be
treated by local excision, such as endoscopic resection [8].
Conventional endoscopic mucosal resection (EMR) has
been the endoscopic treatment of choice for rectal NETs.
However, conventional EMR often produces incomplete
resection of rectal NETs because even small rectal NETs
can invade the submucosa. For this reason, various modi-
fied methods of EMR have been developed for the treat-
ment of small rectal NETs, including EMR after
precutting (EMR-P) and EMR using a dual-channel endo-
scope (EMR-D) [9–11]. Previous studies that assessed the
prognosis of rectal NETs included surgically resected cases
[6–8]. However, the literature has only included limited
information on the efficacy of various EMR modalities
and the prognosis of rectal NETs after EMR.
Therefore, we evaluated the clinical outcomes of EMR
for rectal NETs in terms of the histologically complete
resection (H-CR) rate and the recurrence rate after




We retrospectively reviewed the medical records of all
patients who underwent EMR for rectal NET at Seoul
National University Hospital (SNUH) (Seoul, South
Korea) from January 2002 to March 2015. The inclusion
criteria were as follows: (1) patients were at least 18 years
old at endoscopic treatment, and (2) rectal NET had
been pathologically diagnosed. The following patients
were excluded from the study: (1) those who did not re-
ceive endoscopically complete resection, and (2) those
who received endoscopic resection somewhere other
than our center because we could not assess their clini-
copathologic factors at initial treatment. In clinical prac-
tice, most patients who did not achieved endoscopically
complete resection of rectal NETs receive immediate
additional endoscopic or surgical treatment as salvage
management. Therefore, we focused on the clinical out-
comes of endoscopically resected rectal NETs without
gross lesion.
Endoscopically complete resection was defined as re-
section of the lesion without grossly remnant tumor.
Clinicopathologic and endoscopic data were retrospect-
ively reviewed using the electronic medical records of
our institution. The Institutional Review Board of SNUH
approved this study (1605–052-760).
Endoscopic procedures
All endoscopic procedures were performed by experi-
enced endoscopists who are all gastroenterologist in
SNUH. They have at least a few thousand colonoscopy
experiences. The resection methods for rectal NETs in-
cluded conventional EMR, EMR-P, and EMR-D.
We recommended endoscopic resection for NETs less
than 10 mm in diameter without risk factors for recur-
rence and surgical resection for NETs larger than
20 mm or NETs with central erosion regardless of size.
If the patients with rectal NETs refused surgery, they
underwent endoscopic resection and were followed up
with regular surveillance considering high risk of tumor
recurrence. For rectal NETs of 10 to 20 mm in size, sur-
gery or endoscopic treatment was chosen considering
the risk of tumor metastasis and patient’s preference. In
particular, surgery was strongly recommended as an ini-
tial treatment in rectal NETs, especially greater than
16 mm in size. There is currently no consensus regard-
ing the optimal endoscopic treatment strategy among
various EMR techniques [12–14]. The EMR method
(conventional EMR, EMR-D, EMR-P) was selected ac-
cording to endoscopist’s preference.
Conventional EMR and EMR-P were carried out with a
single-channel colonoscope. EMR-D was carried out with
a daul-channel colonoscope. Saline solution mixed with a
small amount of indigo-carmine and diluted epinephrine
(1:10,000) was injected into the submucosal layer beneath
the tumor to reduce the risk of perforation and resection
margin involvement. Subsequently, in all EMR modalities,
snare resection was performed with an electrosurgical
current. For EMR-D, the lesion was grasped by alligator
forceps; snaring was then performed below the grasping
forceps. For EMR-P, marking dots were made on the cir-
cumference of the lesion by electrocautery using a hook
knife. Mucosal incision in EMR-P enables effective snaring
without slippage of the snare.
Evaluation of outcomes
The primary outcomes were H-CR and recurrence rates
after endoscopic resection. Secondary outcomes were addi-
tive treatment for histologically incomplete resection (H-IR),
procedure-related complications, and disease-related deaths.
All specimens were originally read by board-certified pa-
thologists at SNUH between 2002 and 2015. Ancillary im-
munohistochemical (IHC) staining including D2–40,
CD34, and CD31 in addition to hematoxylin and eosin
(H&E) histologic examination was done to evaluate LVI in
rectal NETs, if it is difficult or ambiguous to determine
the presence of LVI in H & E staining. The tumor size,
depth of invasion, resection margin status, differenti-
ation, and presence of LVI were determined on the
basis of the pathologic reports. H-CR was defined as
being present when the lateral and deep margins of
the specimens were free of tumor invasion. H-IR was
considered to be present in all other cases. Maximum
diameter was used as the measure for tumor size.
Pathologic diagnosis was graded according to the
2010 World Health Organization (WHO) classification
of tumors of the digestive system [15].
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Local recurrence was defined as a pathologically con-
firmed diagnosis of NET at the same site more than
6 months after the initial treatment. If recurrence was
diagnosed at the same site within 6 months after initial
treatment, recurrence of rectal NET was considered as
residual lesion rather than local recurrence.
Procedure-related complications were assessed, includ-
ing bleeding and perforation. Procedure-related bleeding
was classified as immediate when bleeding did not stop
spontaneously and required intervention including argon
plasma coagulation, electrocauterization, or hemoclips.
Procedure-related bleeding was classified as delayed
when bleeding occurred later than 24 h after endoscopic
resection. Perforation was readily observed endoscopic-
ally or detected based on the presence of free air on a
plain radiograph taken after the procedure.
Follow-up
Subsequent treatments, including additional endoscopic
resection or surgery, were recommended if H-IR or LVI
were detected based on pathological results.
Patients who refused surgery received close observa-
tion with short-term endoscopic examination. Patients
continued to undergo periodic follow-up with colonos-
copy or sigmoidoscopy, and/or abdominal computed
tomography (CT) scanning.
Statistical analysis
The χ 2 or Fisher’s exact test was used to assess relation-
ships among categorical variables, and the t test or
Mann-Whitney U test was used for noncategorical vari-
ables. A multivariate logistic regression analysis was used
to identify factors that were associated with H-CR. Vari-
ables with p-values less than 0.2 in the univariate ana-
lysis were considered for entry into the final multivariate
analysis. The analysis results are presented as odds ratios
(ORs) with 95% confidence intervals (CIs). Statistical
analysis was performed using the Statistical Package for
the Social Sciences software, version 15.0 for Windows
(SPSS, Chicago, IL). Results were considered to be statis-
tically significant for 2-sided p-values of less than 0.05.
Results
Patient selection
A total of 350 patients who underwent EMR for rectal
NETs were initially included in our study. However, the
following 73 patients were excluded from our analysis: 3
patients who did not achieve endoscopically complete
resection and 70 patients who had undergone endo-
scopic resection at an outside hospital. Thus, a total of
277 patients were included in the initial analyses of
H-CR efficacy and factors contributing to H-CR for
rectal NETs. Of these 277 patients, 183 (66.1%) under-
went at least 1 endoscopic follow-up. Finally, these 183
patients were included in the assessment of long-term
prognosis. A flow chart of the study inclusions and ex-
clusions is shown in Fig. 1.
Clinicopathologic characteristics
In the cohort of 277 patients, the median age at diagno-
sis was 50.9 years (range, 26–79) and 170 (61.4%) of the
patients were male. The median distance from the anal
verge was 7.1 cm (range, 1–16). Of the 277 patients, 243
(87.7%) were treated with conventional EMR, 23 (8.3%)
with EMR-D, and 11 (4.0%) with EMR-P. Regarding the
number of resection fragments, en-bloc resections were
performed in 274 (98.9%) cases and piecemeal resections
in the remaining 3 cases (1.1%).
The histologically estimated median tumor size was
4.96 mm (range, 1–22) in diameter. Rectal NETs less
than 10 mm, 10–19 mm, and at least 20 mm in diameter
were observed in 256 (92.4%), 20 (7.3%), and 1 (0.3%)
patients, respectively. The histological assessments of re-
section margins indicated H-CR in 206 (74.4%) patients.
LVI was found in 14 (5.1%) patients. According to the
WHO classification, grade (Gr) 1 was found in 246
(88.8%) patients and Gr 2 in 3 (1.1%) patients The mi-
totic index was assessed in 211 (76.2%) patients, of
whom only 9 (4.3%) were noted as having a high mitotic
index (≥2/10 high-power field). Three (1.1%) patients
had synchronous rectal NETs at initial diagnosis, and
those lesions were removed at the initial endoscopic re-
section. Tumor invasion was confined to the submucosal
layer in 269 (97.3%) patients.
Of the 277 patients, 183 (66.1%) continued to undergo
follow-up colonoscopy or sigmoidoscopy. The median
follow-up period was 32.1 months (range, 2.3–146.0).
The clinicopathologic characteristics of the patients who
underwent endoscopically complete resection for rectal
NET are summarized in Table 1.
Fig. 1 Flow chart showing the inclusion of study patients
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Clinical outcomes
The overall rate of H-CR was 74.4%. A total of 3 patients
underwent additive surgery at 1.1 months (range, 0.4–2.3)
after initial endoscopic resection because the pathologic
examination showed presence of NET cells at the resec-
tion margin (n = 2) and LVI (n = 1). Only 1 of the patient
who underwent surgery after initial endoscopic resection
had residual tumor on the surgical specimen. Based on
endoscopic examination, this patient had not been sus-
pected of having residual disease before surgery. No re-
sidual tumor was found in other 2 patients.
Complications occurred after endoscopic resection in 11
patients (4.0%). All complications were procedure-related
bleeding, and 1 patient had delayed bleeding. All bleeding
events were successfully managed by endoscopic clipping
or coagulation therapy. There was no perforation after
treatment.
Factors associated with histologically complete resection
In our analysis of pathologic results, 206 (74.4%) patients
were included in the H-CR group and 71 (25.6%) pa-
tients were included in the H-IR group. Table 2 shows
factors associated with H-CR.
There were no significant differences between the 2
groups in terms of age, gender, gross type of tumor, or
distance from the anal verge. Further, there was no sig-
nificant difference between the H-CR and H-IR groups
in terms of procedure-related complications (7 [3.4%]
for H-CR vs 4 [5.6%] for H-IR, p = 0.481) or recurrence
(2 [1.0%] for H-CR vs 2 [2.8%] for H-IR, p = 0.272). The
median tumor size was significantly smaller in the H-CR
group than in the H-IR group (p = 0.009).
The following variables had p-value less than 0.2 in
the univariate analysis of associations with H-CR: tumor
size, en-bloc resection, and presence of synchronous rec-
tal NETs. However, when these variables were entered
into a multivariate analysis, only tumor size remained
significantly associated with H-CR (Table 3).
The H-CR rate according to endoscopic treatment
modalities is shown in Table 4. The H-CR rate for rectal
NETs in the conventional EMR group was 74.5%, which
was similar to that in the EMR-D group (73.9%) and the
EMR-P group (72.7%). There was no statistically signifi-
cant difference in H-CR rates among the conventional
EMR, EMR-D, and EMR-P groups (conventional EMR
vs EMR-D, p = 0.114; conventional EMR vs EMR-P, p =
1.000; EMR-D vs EMR-P, p = 1.000).
Clinical outcomes during follow-up
During a median follow-up period of 32.1 months
(range, 2.3–146.0), 183 (66.1%) patients were followed
by endoscopic evaluation. Three (1.6%) patients devel-
oped tumor recurrence during the follow-up period, at a
Table 1 The clinical and clinicopathologic characteristics of the
patients who underwent endoscopically complete resection for
rectal NETs
Variables No.
Age, median (range), years 50.9 (26–79)
Gender, male 170 (61.4%)
Endoscopic appearance
Polyp 22 (7.9%)
Submucosal tumor 255 (92.1%)
Distance from anal verge, median (range), cm 7.1 (1–16)
Treatment modalities
Conventional EMR 243 (87.7%)
EMR-D 23 (8.3%)
EMR-P 11 (4.0%)
En-bloc resection 274 (98.9%)
Tumor size, median (range), mm 4.96 (1–22)
Group according to tumor size (%)
< 10 mm 256 (92.4%)
10–19 mm 20 (7.3%)
≥20 mm 1 (0.3%)
Histologically complete resection 206(74.4%)
Negative lateral margin 240 (86.6%)








Not described 30 (10.8%)
Mitotic count
< 2/10 202 (72.9%)
≥ 2/10 9 (3.2%)
Not described 66 (23.8%)
Presence of synchronous rectal NETs 3 (1.1%)
Tumor depth
Limited to mucosa 5 (1.8%)
Submucosa 264 (95.3%)
Muscularis propra or deeper 0 (0%)
Indeterminate 8 (2.9%)
Follow-up 183 (66.1%)
Follow-up duration, median (range), months 32.1 (2.3–146.0)
Values are presented as median (range) or as numbers (%)
Abbreviations: EMR endoscopic mucosal resection, EMR-D EMR using a dual-
channel endoscope, EMR-P endoscopic mucosal resection after precutting, Gr
grade, NET neuroendocrine tumor
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median of 62.5 months (range 18.5–98.0) after endo-
scopic resection.
Two of the 3 patients had local recurrence, while the
remaining patient had distant metastasis to the liver and
bone. All of these patients had tumors less than 10 mm
in diameter confined to the submucosal layer and were
treated with en-bloc resection: one patients underwent
conventional EMR and 2 patients underwent EMR-D. In
the pathologic examination, no patient had a high mi-
totic index. Among 2 patients who achieved H-CR at the
initial endoscopic resection, one patient had no LVI and
the other one had indeterminate LVI status. The 3
patients with recurrence received additive treatments: 2
underwent EMR and 1 underwent liver metastasectomy.
One patient with residual lesion diagnosed at 2 months
follow-up did not achieved H-CR and underwent add-
itional electrocauterization as salvage treatment. All the
patients with local recurrences and residual lesion
remained free of disease during a median follow-up dur-
ation of 118.9 (range 60–167.3) months.
There was 1 disease-related death, which occurred
156 months after the endoscopic treatment because of
bone marrow failure that resulted from tumor metastasis.
The NET of this patient measured 5 mm in diameter
without depression, ulceration, or a high mitotic index,
and was assessed as endoscopically complete resection but
not H-CR. Because the patient refused surgical resection,
he underwent annual follow-up with sigmoidoscopy and
abdominal ultrasonography. Seventy months after initial
endoscopic treatment, metastasis in the liver was found
on abdominal CT, while there was no evidence of local re-
currence at sigmoidoscopy. The patient underwent liver
metastasectomy. Surgical specimens from liver metasta-
sectomy showed no evidence of LVI. However, the patient
died 8 years after metasectomy because of disease pro-
gression in the liver and bone marrow.
Discussion
It is well-known that rectal NETs have the smallest size
of all gastrointestinal NETs [16]. Moreover, rectal NET
was found to have the best prognosis of all NETs, with a
5-year survival rate of 88.2% [2]. For this reason, and be-
cause of the extremely low risk of lymph node metasta-
sis, local excision is considered to be a sufficient
treatment for lesions less than 10 mm in diameter [5].
However, there are currently no widely used guidelines
regarding the management of rectal NETs 10–20 mm in
diameter [17, 18].
Conventional EMRs cannot remove tumors with free
vertical margins because of the presence of submucosal
layer involvement, and increase the need for further treat-
ment [19, 20]. As applied for deep resection of rectal
NETs, endoscopic submucosal dissection (ESD) requires a
long learning period, specific devices, and longer proced-
ure times than conventional EMR. Therefore, several new
Table 2 Factors associated with histologically complete
resection
Variables H-CR (n = 206)
(n, %)





50.0 (26–79) 52.7 (26–73) 0.33
Gender, male 123 (59.7%) 47 (66.2%) 0.333
Endoscopic appearance 0.489
Polyp 15 (7.3%) 7 (9.9%)
Submucosal tumor 191 (92.7%) 64 (90.1%)
Distance from anal verge,
median, cm
6.3 (1–16) 6.0 (1–15) 0.852
Tumor size, median, mm 4.7 (1–22) 5.7 (2–12) 0.009
En-bloc resection 205 (99.5%) 69 (97.2%) 0.162
Lymphovascular invasion 0.215
Yes 10 (4.9%) 4 (5.6%)
No 180 (87.4%) 57 (80.3%)
Indeterminate 15 (7.7%) 10 (14.1%)
Grade 0.668
Gr1 185 (89.8%) 61 (85.9%)
Gr2 2 (1.0%) 1 (1.4%)
Not described 19 (9.2%) 9 (12.7%)
Mitotic count N/A
< 1/10 148 (94.3%) 54 (100.0%)
≥ 1/10 9 (5.7%) 0 (0.0%)
Presence of synchronous
rectal NETs
1 (0.5%) 2 (2.8%) 0.162
Values are presented as median (range) or as numbers (%)
Abbreviations: H-CR histologically complete resection, H-IR histologically
incomplete resection, N/A not applicable, NET neuroendocrine tumor
Table 3 Multivariate analysis to determine factors associated
with histologically complete resection
OR (95% CI) p value
Tumor size 0.90 (0.82–0.99) 0.023
En-bloc resection 4.47 (0.39–51.5) 0.230
Presence of synchronous rectal NETs 5.17 (0.45–58.9) 0.186
Abbreviations: CI confidence intervals, NET neuroendocrine tumor, OR
odds ratio
Table 4 Histologically complete resection rates according to
endoscopic treatment modalities
H-CR rate, n (rate, %) p value
Treatment modalities 0.99
Conventional EMR 181/243 (74.5%)
EMR-D 17/23 (73.9%)
EMR-P 8/11 (72.7%)
Abbreviations: H-CR histologically complete resection, EMR endoscopic mucosal
resection, EMR-D EMR using a dual-channel endoscope, EMR-P endoscopic
mucosal resection after precutting
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endoscopic modalities have been developed, including
EMR-D, EMR-P, and endoscopic submucosal resection
with a ligation device (ESMR-L). These new modalities are
reported to be effective for complete resection, as com-
pared with ESD [21–23].
To date, several studies have reported factors that are
associated with H-CR or prognosis in cases of rectal
NET treated with endoscopic resection, including results
for different treatment modalities [14, 21–24]. However,
the studies have been limited by their small study co-
horts. Previous study showed that treatment modality
was the only factor that showed an independent associ-
ation with the H-CR rate of small rectal NETs [24]. A
meta-analysis indicated that ESD or modified EMRs (in-
cluding EMR-D, EMR-L, EMR using a transparent cap,
and ESMR-L) are superior to EMR, and that the efficacy
of modified EMR nearly equals that of ESD in terms of
the H-CR rate [14]. The efficacy of conventional EMR is
known to be insufficient to remove rectal NETs by 64–
82% of the H-CR rate [25–27]. According to previous
studies, the H-CR rate of EMR-P and EMR-D were 87–
100% and 74–83%, respectively [13, 25]. However, in the
present study, we found that H-CR rates were 72–74%
for various EMR procedures, and that only tumor size
was significantly associated with the H-CR rate. We did
not observe any significant differences in the H-CR rate
among the conventional EMR, EMR-D, and EMR-P
groups. Compared with the previous studies, the rela-
tively high H-CR rate of conventional EMR and rela-
tively low H-CR rate of modified EMR observed in this
study might to be due to considerable proficiency in
conventional EMR of our hospital. According to previ-
ous studies, the resection time is significantly longer for
modified methods of endoscopic resection (including
EMR-P, EMR-D, ESMR-L, and ESD) than for conven-
tional EMR [23, 28]. If a physician has a relatively high
H-CR rate of the conventional EMR due to lots of ex-
perience, the physician should be cautious about accept-
ing a modified EMR unconditionally, considering that
modified EMR techniques require longer procedure time
and more equipment than conventional EMR.
In the present study, there were a total of 3 recurrences
among the patients whose rectal NETs were completely
removed through endoscopy, and who underwent at least
1 follow-up endoscopy. Two of the recurrences were local
and 1 was a distant metastasis, with an overall median
time to recurrence of 62.5 months. According to previous
reports, the recurrence rate after endoscopic resection for
rectal NET is approximately 0–4.2% [8, 14, 29, 30]. In a
study of 304 patients with a median follow-up of
48 months, Park et al. reported 2 cases of recurrence after
endoscopic resection for rectal NETs [31]. In a study of
153 lesions with a median follow-up of 31.0 months, Son
et al. reported neither local recurrence nor metastasis to
the regional lymph nodes or distal organs [24]. In a
meta-analysis of 687 patients who rectal NETs were re-
moved by endoscopic treatment, 6 patients had tumor re-
currence during follow-up [14]. In our study, the
recurrence rate after endoscopically complete resection
was 1.6%, which is similar to the values that have been re-
ported elsewhere [8, 14, 24, 31].
Of note, all cases of recurrence in our study involved a
small tumor size (less than 10 mm in diameter), had a
low mitotic index, and were confined to the submucosal
layer. Our results differ from the recommendations of
recent guidelines in terms of the development of tumor
recurrence [32]. For example, follow-up is not recom-
mended for rectal NETs less than 10 mm in diameter ac-
cording to the National Comprehensive Cancer Network
guidelines [32]. However, our study included 2 local re-
currences, 1 residual lesion and 1 distant metastasis that
led to death, all of which were observed among small
rectal NETs (less than 10 mm) after endoscopic resec-
tion, and 1 of which even occurred after 8 years. More-
over, H-CR was also achieved in 2 of 3 recurrence cases.
The possibility of an unexpected recurrence might be
explained by the underestimated LVI state. Although a
complete pathology reexamination using specific stain-
ing for LVI was not possible, 1 case of local recurrence
with achieving H-CR and 1 case with residual lesion
were confirmed not to accompany LVI by H&E staining
with CD-34 staining. However, recently, the problem
that LVI status in small rectum NET is not always accur-
ately evaluated without special staining for LVI has been
raised. D2–40 and CD-31 are the most useful specific
marker for detect LVI in NETs [33]. According to recent
study analyzed the LVI state in small rectal NETs using
these IHC staining, LVI in small rectal NETs was ob-
served in 46.7% of the cases [34]. However, recently pub-
lished study in Korea, LVI rates in small rectal NETs
were 25.0 and 27.9% in H&E and ancillary IHC staining,
respectively. In this study, the concordance rate between
2 staining methods was 81.7% for detection of LVI, with
strong agreement [33]. Even so, the low rate of LVI of
rectal NETs observed in our study might be due to
underestimated LVI assessment. When reviewed retro-
spectively, ancillary IHC staining, including D2–40, and
CD31, was selectively performed in approximately 30%
of patients in this study. The diagnosis of LVI during
pathologic evaluation may be underestimated. In clinical
practice, careful attention including confirmation using
special staining for LVI should be paid to the interpret-
ation of LVI.
All local recurrence cases in our study were treated by
endoscopic resection, not by salvage operation. In
principle, salvage operation should be recommended to
patients with rectal NETs with unfavorable factors of re-
currence such as H-IR, high mitotic index, or LVI.
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However, there has been no consensus on the appropri-
ate salvage treatment for local recurrence of rectal NETs.
In this study, 2 local recurrence cases were all small
NET less than 10 mm and even in 1 case, there were no
unfavorable factors of tumor recurrence. However, 1 of
these 2 cases with local recurrence had indeterminate
LVI state, and 1 case with residual lesion did not
achieved H-CR. They also received endoscopic resection
instead of surgery as salvage treatment. In real practice,
many physicians facing indeterminate pathologic results
choose additional endoscopic resection as salvage treat-
ment of local recurrence, considering the preference of
patients receiving endoscopic treatment, concerns about
surgical risks, and the ease of access to endoscopy in
South Korea. One residual lesion case with H-IR was
also treated by endoscopic method. Gastroenterologists
might not consider positive resection margin as a high
risk factor for recurrence of tumor because of the
cauterization effect of endoscopic resection.
A close relationship has been noted between tumor
size and risk of metastasis [3, 7, 35]. Jetmore et al. noted
that none of 56 patients with tumors less than 10 mm in
size developed metastatic disease during a 32-year
follow-up period [36]. However, Naunheim et al. raised
concerns regarding the issue of size for NETs. They
found that 13 (3.4%) of 388 patients with rectal NETs
smaller than 10 mm in diameter had either metastatic
disease on presentation or developed metastatic disease
[37]. Although the risk of metastasis from small rectal
NETs is generally low, some patients—even those with
NETs smaller than 10 mm—may show metastasis [8].
Although small tumors generally have a benign course,
post-excision recurrence developed for 4 (2.6%) of 152
tumors smaller than 10 mm in our study, which serves
as a reminder that the behavior of these tumors is not
easily predicted. Previous studies suggested that residual
macroscopic disease is a poor prognostic factor [38].
However, in our study, 97.2% patients with H-IR were
free of local recurrence and distant metastasis on
follow-up, raising the question of whether H-CR is re-
quired to prevent disease progression. However, given
the small number of cases with recurrence, further stud-
ies about the recurrence of rectal NETs after endoscopic
resection are warranted to confirm this finding.
A recent study revealed that synchronous rectal NET
at the initial diagnosis was associated with the develop-
ment of development of metachronous rectal NETs [17].
Similar results were found in studies of colorectal aden-
oma. According to previous studies of metachronous
colorectal adenoma after resection for colorectal cancer,
synchronous colorectal adenoma is a risk factor for the
development metachronous lesions [39, 40]. However, in
our study, the presence of synchronous rectal NETs did
not have a statistically significant association with NET
recurrence after endoscopic resection. Nonetheless, our
study included few cases of synchronous rectal NETs,
which suggests that further investigation is needed with
larger sample sizes.
There present study has several limitations. First, this
was a single-center study, and the cases of rectal NETs
in the modified EMR groups and the recurrence group
were relatively small. For this reason, we could not
analyze risk factors for recurrence after endoscopic re-
section. Although, we compared the efficacy of each
EMR methods, there is a limitation that statistical power
of this analysis is limited by numbers of patients in the
modified EMR groups. Further studies should be needed
to compare the efficacy among EMR techniques with a
greater number of patients.
Second, because this study had a retrospective design,
strategies for staging work-ups and surveillance were not
standardized. The follow-up schedules may have differed
across clinicians because there has not been any consen-
sus regarding treatment strategies or surveillance for
rectal NETs, in general. In addition, since the patients
with rectal NETs were diagnosed over a long period of
time in this study, a single criteria for the surveillance
after initial treatment could not be applied to all pa-
tients. Accordingly, we decided to include patients who
underwent at least 1 follow-up endoscopic evaluation in
our analysis of clinical outcomes during follow-up.
Third, the duration of follow-up, which is not long
enough to assess recurrence of NETs, is limitation of our
study. The median follow-up period of our study was
32.1 months (range, 2.3–146.0). In previous studies
reporting clinical course after rectal NETs treatment, the
median follow-up period ranged from 5 to 70 months.
The follow-up period of our study is not comparatively
short compared to the previous reports, however, the
follow-up periods in our study varied widely, and some
patients may have had relatively insufficient durations of
follow-up. Considering the characteristics of slow grow-
ing rectal NETs and recurrence occurred after several
years of initial treatment, a short follow-up period is a
limitation of this study. Further study with longer
follow-up periods should be needed to more accurately
evaluate the recurrence risk of rectal NETs after endo-
scopic resection. However, the fact that several recur-
rences of rectal NETs after initial treatment were
observed despite the relatively short follow-up period
seems to be sufficient to raise awareness of monitoring
for rectal NET recurrence. Fourth, this study did not in-
clude patients who underwent ESD and other modified
EMR techniques such as ESMR-L and cap-assisted EMR
(EMR-C). The aim of this study was to evaluate the effi-
cacy of various EMRs on rectal NETs treatment, we ex-
cluded the patients with rectal NETs by resected by
ESD. Because inter-endoscopist variation can have
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especially strong effects on clinical outcomes for ESD,
which requires a high level of technical expertise as dis-
cussed previously [41]. Moreover, the inclusion period of
this study was relatively long; had we extended the study
to ESD, it may have required including early experiences
with this modality. ESMR-L and EMR-C, which are
known to be as convenient as conventional EMR, were
not performed in our hospital due to the preference of
the physicians. In particular, ESMR-L consistently
showed a high H-CR rate of more than 90% in several
studies. Therefore, further studies including various
other EMR techniques such as ESMR-L and EMR-C are
needed to confirm the efficacy of other modified EMR
techniques not evaluated in this study [21, 42].
Despite these limitations, our study has important
strengths: it is the largest single-center investigation of
rectal NETs treated with EMR, and it includes a rela-
tively long follow-up period with endoscopic examin-
ation. To the best of our knowledge, this is the first
study of rectal NETs after EMR that has included ana-
lyses of the H-CR rate, factors associated with H-CR,
and long-term prognosis after EMR.
Conclusions
In conclusion, although the en-bloc resection rate was
99% for rectal NETs, H-CR rates were 72–74% for the
investigated EMR procedures. H-CR may be associated
with tumor size regardless of endoscopic treatment mo-
dalities. Further large-scale studies are needed to identify
risk factors for recurrence after endoscopic resection,
which will help to establish guidelines for the treatment
of small rectal NETs.
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